Vol. 2 No. 10 (2022)
Reimbursement Reviews

Cariprazine (Vraylar)

Published October 12, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Cariprazine (Vraylar) 5 mg, 3 mg, 4.5 mg, and 6 mg oral capsules.
  • Indication: For the treatment of schizophrenia in adults.